[Home ] [Archive]    
:: Main :: About :: Current Issue :: Archive :: Search :: Submit :: Contact ::
:: Volume 3, Number 3 (9-2013) ::
Iran J Ped Hematol Oncol 2013, 3(3): 125-134 Back to browse issues page
Rituximab Is Indispensable for Pediatric Heart Transplant Recipients Developing Post transplant Lymphoproliferative Disorders
MD R Karbasi-Afshar , MD S Taheri
Abstract:   (1532 Views)
Abstract Rituximab, an anti-CD20 agent, has been suggested as an effective strategy to deal with post transplant lymphoproliferative disorders (PTLD). In the current study, we aim to evaluate the efficacy of rituximab therapy in heart transplant population developing PTLD. A comprehensive search of the literature was performed to gather the available data on lymphoproliferative disorders occurring in heart transplant patients. Finally, data of 125 patients from 26 previously published studies were included into the study. Patients who underwent rituximab therapy had significantly worse tumoral histopathology features (P-value=0.003). Survival analyses showed no significant difference regarding receiving rituximab therapy for heart recipients however, when the analysis was repeated only including data of pediatric patients, significant beneficial effects for pediatric were found for rituximab therapy. In fact, no children undergoing rituximab therapy died during the follow up. In conclusion, this study showed that rituximab therapy in pediatric heart transplant recipients with PTLD represents surprisingly excellent results, making rituximab an indispensable agent in the management of the disease. To define feasibility of rituximab therapy in adult recipients of heart graft with PTLD, randomized controlled trials are needed.
Keywords: Pediatrics; Heart Transplantation; rituximab
Full-Text [PDF 178 kb]   (642 Downloads)    
Type of Study: Research | Subject: Special
Received: 2013/09/14 | Accepted: 2013/09/18 | Published: 2013/09/18
Add your comments about this article
Your username or email:

Write the security code in the box >



XML     Print


Download citation:
BibTeX | RIS | EndNote | Medlars | ProCite | Reference Manager | RefWorks
Send citation to:

Karbasi-Afshar R, Taheri S. Rituximab Is Indispensable for Pediatric Heart Transplant Recipients Developing Post transplant Lymphoproliferative Disorders. Iran J Ped Hematol Oncol. 2013; 3 (3) :125-134
URL: http://ijpho.ssu.ac.ir/article-1-139-en.html
Volume 3, Number 3 (9-2013) Back to browse issues page
Iranian Journal of Pediatric Hematology and Oncology
Persian site map - English site map - Created in 0.209 seconds with 827 queries by yektaweb 3506